Fate Therapeutics Inc. (FATE)
0.91
-0.06 (-5.83%)
At close: Mar 18, 2025, 3:59 PM
0.93
2.04%
After-hours: Mar 18, 2025, 07:55 PM EDT
-5.83% (1D)
| Bid | 0.9 |
| Market Cap | 104.73M |
| Revenue (ttm) | 13.5M |
| Net Income (ttm) | -184.44M |
| EPS (ttm) | -1.64 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | -0.8 |
| Analyst | Hold |
| Ask | 0.96 |
| Volume | 831,811 |
| Avg. Volume (20D) | 2,615,774 |
| Open | 0.95 |
| Previous Close | 0.97 |
| Day's Range | 0.90 - 0.95 |
| 52-Week Range | 0.87 - 7.70 |
| Beta | 2.26 |
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat mul...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2013
Employees 181
Stock Exchange NASDAQ
Ticker Symbol FATE
Website https://www.fatetherapeutics.com
Analyst Forecast
According to 9 analyst ratings, the average rating for FATE stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 447.11% from the latest price.
Stock ForecastsNext Earnings Release
Fate Therapeutics Inc. is scheduled to release its earnings on May 8, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
+2.64%
Fate Therapeutics shares are trading higher after ...
Unlock content with
Pro Subscription
4 months ago
+12.38%
Fate Therapeutics shares are trading higher after the company presented 6-month follow-up data on the first patient treated in its Phase 1 Autoimmunity study.
